Exchange: Other OTC Sector: Healthcare Industry: Medical - Diagnostics & Research
-8.34% $1.423
/ 25 apr 2024 @ 15:38
FUNDAMENTALS | |
---|---|
MarketCap: | 6.23 mill |
EPS: | 0.260 |
P/E: | 5.47 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 4.38 mill |
Avg Daily Volume: | 0.0057 mill |
RATING 2024-04-25 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Strong Buy | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 5.47 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 5.47 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.328 - 1.512 ( +/- 6.48%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Mccarthy Christopher | Buy | 10 000 | Common Stock |
2023-07-31 | Mccarthy Christopher | Buy | 25 000 | Common Stock |
2023-04-21 | Mccarthy Christopher | Sell | 0 | Common Stock |
2023-04-21 | Mccarthy Christopher | Sell | 2 500 | Stock Option (right to buy) |
2023-04-21 | Mccarthy Christopher | Sell | 5 000 | Restricted Stock Units |
INSIDER POWER |
---|
73.53 |
Last 82 transactions |
Buy: 3 273 782 | Sell: 3 181 326 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $1.423 (-8.34% ) |
Volume | 0.0024 mill |
Avg. Vol. | 0.0057 mill |
% of Avg. Vol | 41.66 % |
Signal 1: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.